The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
April 26th 2024
Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Dr Jan Hillert Discusses Treatment Approaches in MS
October 28th 2019Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses whether the medical community has reached a consensus on using an escalation approach to treatment or starting with highly effective therapies in treating multiple sclerosis (MS).
Watch
Using Serum Neurofilament Light Chains as a Biomarker of MS Disease Activity
October 23rd 2019Serum neurofilament light chain is associated with brain atrophy and disability worsening, which means it can be used as an objective surrogate of ongoing disease activity in multiple sclerosis (MS), according to research published in JAMA Neurology.
Read More
Dr Jan Hillert Addresses Stem Cell Transplants in Treating MS
October 14th 2019Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses the body of knowledge on using stem cell transplants to treat patients with multiple sclerosis (MS).
Watch
Treatment Patterns and Risk of Comorbidity Among Newly Diagnosed Patients With MS
October 12th 2019Two abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, looked at patterns among patients newly diagnosed with multiple sclerosis (MS).
Read More
Comparing Efficacy of Ozanimod on Annualized Relapse Rate With Other DMTs
October 2nd 2019Ozanimod, under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Read More
Dr Daniel Kantor Outlines Ways to Measure Disease Progression in MS
October 1st 2019When measuring disease severity and progression in patients with multiple sclerosis (MS), there are several approaches that provide different information and have varying strengths and weaknesses, according to Daniel Kantor, MD, president of Kantor Neurology.
Watch
Dr Daniel Kantor Discusses the Troubling Occurrence of MS Underdiagnosis
September 24th 2019While there are concerns about the overdiagnosis of multiple sclerosis (MS), underdiagnosis is also a serious problem that can lead to patients not receiving treatment for MS, explained Daniel Kantor, MD, president of Kantor Neurology.
Watch
Dr Daniel Kantor on the Real-World Value of MS Disease Registries
September 16th 2019Since the introduction of disease-modifying therapies for multiple sclerosis (MS), evidence from disease registries has shown how the therapies work in the real world and reduce the effect of MS on people’s lives, according to Daniel Kantor, MD, president of Kantor Neurology.
Watch
Dr Thomas Frisell Addresses Cardiac Safety of Ozanimod Versus Fingolimod in MS
September 13th 2019Patients with multiple sclerosis (MS) have a generally increased risk of cardiovascular disease, and some evidence is emerging that disease-modifying treatments may alter this risk. Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether newer treatments for MS, such as ozanimod, may present an improved cardiac safety profile for patients with MS versus older treatments, such as fingolimod.
Watch
Dr Andrew Solomon Discusses the Correct Application of the McDonald Criteria in Diagnosing MS
September 13th 2019Multiple sclerosis (MS) can be a challenging disease to diagnose because of its broad range of symptoms and because of the fact that many other syndromes can mimic MS. Additionally, the McDonald Criteria, which are clinical, radiographic, and laboratory criteria used for diagnosing MS, are sometimes misapplied, according to Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Watch
More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS
September 12th 2019Results for ozanimod, which is under review by FDA and European regulators for treatment of relapsing multiple sclerosis (MS), were presented in poster sessions September 12, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Read More
Dr Viktor von Wyl Addresses the Impact of MS Disease Duration and Age on Disability Burden
September 12th 2019Age is an important factor in the disease burden of multiple sclerosis (MS), as rising age both impacts disease course and brings with it additional risk of comorbidities. However, disease duration may be an even more important factor than age in reaching disability milestones, according to Viktor von Wyl, PhD, project leader, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Watch
Inebilizumab Results for NMOSD Presented at ECTRIMS, With Public Offering on Way
September 12th 2019FDA recently accepted the Biologics Licensing Application for inebilizumab to treat a rare autoimmune condition, neuromyelitis optica spectrum disorder. The results for inebilizumab were presented at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Read More
Dr Jan Hillert Discusses Emerging Therapeutic Targets for MS
September 12th 2019While current therapies for multiple sclerosis (MS) that treat focal inflammation are beneficial for many patients, there are other crucial aspects of the disease, including brain volume loss, that are not clearly linked to this inflammation and that demand new therapeutic developments, said Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden.
Watch
Better Therapies, Management of Comorbidities Improving Long-term Outcomes in MS, Speakers Say
September 12th 2019Speakers at a session at ECTRIMS 2019 on long-term outcomes in multiple sclerosis said that better therapies and improved understanding of the effect of comorbidities have improved outcomes. The session was part of the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Read More
Bringing Real-World Data to Multiple Sclerosis Treatment Decisions
September 11th 2019Maria Trojano, MD, professor of neurology at the University of Bari, Italy, offered the opening lecture at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Read More
Measure From RADIANCE Data Suggests Ozanimod More Effective in Slowing MS Disease Activity
September 11th 2019A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Read More
Dr Deborah Taira Addresses Patient Demographics and Comorbidities in MS
September 11th 2019Addressing comorbidities plays an important role in the management of patients with multiple sclerosis (MS), particularly given their association with hospital admissions. In a study using data from the National Patient Sample, comorbidities were linked with patients’ age, sex, and race and ethnicity, said Deborah Taira, MPA, ScD, professor, Daniel K. Inouye College of Pharmacy, University of Hawai‘i at Hilo.
Watch
Dr Marie D'hooghe Discusses How Pregnancy Affects Disease Course in Patients With MS
September 11th 2019Some data suggest that pregnancy may be beneficial in the long-term for patients with multiple sclerosis (MS), but there exist periods that may carry an extra risk of relapse, such as before conception and in the postpartum period, according to Marie D’hooghe, MD, PhD, neurologist at the National MS Center, Melsbroek, in Brussels, Belgium, and consultant neurologist at the University Hospital in Brussels, Belgium.
Watch
Dr Daniel Kantor Explains How MS Measurement and Prediction Can Lead to Precision Medicine
September 10th 2019Using imaging, laboratory testing, and predictive models, the field of multiple sclerosis (MS) is getting closer to predicting the course of MS and, eventually, the best medication for a given patient, said Daniel Kantor, MD, president of Kantor Neurology.
Watch
Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline
September 7th 2019The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
Watch
This Week in Managed Care: August 30, 2019
August 30th 2019This week, the top managed care stories included a huge ruling against one opioid maker and a settlement offer from another; an expert panel calling for broader screening for hepatitis C; a review showing there are more fatal events linked to a multiple sclerosis drug than previously known.
Watch